In a report released today, Mohan Naidu from Oppenheimer maintained a Buy rating on Athenahealth (NASDAQ: ATHN), with a price target of $179. The company’s shares closed yesterday at $159.79, close to its 52-week high of $163.94.
According to TipRanks.com, Naidu is a 5-star analyst with an average return of 13.4% and a 61.0% success rate. Naidu covers the Services sector, focusing on stocks such as Tivity Health Inc, Hms Holdings Corp, and Express Scripts.
Currently, the analyst consensus on Athenahealth is Moderate Buy and the average price target is $159.75, representing a 0.0% downside.
In a report issued on June 6, Piper Jaffray also maintained a Buy rating on the stock with a $179 price target.
See today’s analyst top recommended stocks >>
Based on Athenahealth’s latest earnings release for the quarter ending March 31, the company reported a quarterly net profit of $31.1 million. In comparison, last year the company had a GAAP net loss of $1.4 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
athenahealth, Inc. engages in the provision of cloud-based business services and mobile applications for medical groups and health systems. It offers network-based medical record, revenue cycle, patient engagement, care coordination, population health services, and other point-of-care mobile applications.
